Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 17%
Buy 17%
Hold 50%
Sell 17%
Strong Sell 0%

Bulls say

RxSight Inc. has demonstrated a strong financial performance, evident from a gross margin increase to 71.6%, which is above consensus expectations and reflects a year-over-year improvement of 980 basis points. The company experienced a significant revenue boost, with Light Adjustable Lens (LAL) revenue reaching $28.5 million, a 60% increase, while Light Delivery Device (LDD) revenue remained stable at $10.7 million, up 7%. Analysts project that RxSight can maintain double-digit growth due to rising utilization rates among an expanding LDD installed base, alongside anticipated improvements in margins driven by higher volumes of LAL sales.

Bears say

RxSight Inc. has demonstrated a concerning deceleration in LAL utilization growth, which dropped to 9% year-over-year in 4Q24, down from the previous range of 17%-22% observed in preceding quarters. The company has also reported stagnant or declining U.S. IOL sales amidst challenging market conditions, exacerbating concerns regarding its market share and revenue growth potential. Additionally, decreased earnings per share estimates for 2025 and 2026, along with risks including clinical challenges, competition, and potential dilutive financing, further reinforce a negative outlook for the company’s financial stability.

RxSight (RXST) has been analyzed by 12 analysts, with a consensus rating of Hold. 17% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Hold based on their latest research and market trends.

According to 12 analysts, RxSight (RXST) has a Hold consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.